The Role of Type 2 Inflammation in COPD and Potential Clinical Implications of Targeted Treatment

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/NZZ865. CME/MOC/AAPA credit will be available until December 28, 2024.

Cracking the Code in COPD: Understanding the Role of Type 2 Inflammation and Potential Clinical Implications of Targeted Treatment

In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support
This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc and Sanofi.

Disclosure Policy
All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures
Chair/Planner
Fernando J. Martinez, MD, MS, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AstraZeneca; GSK; Polarean, Inc.; and Sanofi/Regeneron Pharmaceuticals Inc.
Grant/Research Support from AstraZeneca; Chiesi USA, Inc.; GSK; and Sanofi/Regeneron Pharmaceuticals Inc.
Speaker for AstraZeneca and GSK.

Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.